Multinational Pharmas Face Loss of Preferential Drug Pricing in China
December 24, 2014 at 15:09 PM EST
Starting next month, China is expected to change the way it sets drug prices, a change that could have a profoundly negative effect on the China revenues of multinational drug companies. For years, MNCs have enjoyed premium pricing in China on drugs that have lost their patent protection elsewhere in the world. The class of preferred generics constitute as much as 70% of MNC drug revenues in China. But in January, China will most likely remove the price differential of these drugs, forcing MNCs to price these drugs at the same level as comparable China generics. More details.... Share this with colleagues: // //